• 대한약학회:학술대회논문집
• /
• 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
• /
• pp.137.1-137.1
• /
• 2003

We investigated immunoactivity of ginkgolides (GLS), the primary active constituent of Ginkgo biloba leaves, against disseminated candidiasis due to Candida albicans. This fungus is a polymorphic opportunistic pathogen. BALB/c mice were induced neutropenia by intraperitoneal (i.p.) injection of cyclophosphamide (CP) 24 hours before an i.p administration of GLS (2 mg/mouse) to the mice. Control mice received diluent (Dulbecco's phosphate saline solution; DPBS) instead of GLS. (omitted)

• Biomolecules & Therapeutics
• /
• 제4권4호
• /
• pp.378-384
• /
• 1996

In vitro activities of LB20304a were compared with those of grepafloxacin (OPC-17116), Q-35, ciprofloxacin, and sparfloxacin against 380 clinical isolates collected from general hospitals in 1996. LB 20304a was the most active agent against gram-positive strains including staphylococci, streptococci and enterococci. LB20304a was also very active against gram-negative bacteria and its activity was comparable to that of ciprofloxacin but better than those of grepafloxacin, Q-35 and sparfloxacin. The therapeutic effect of LB20304a was superior to those of sparfloxacin and ciprofloxacin against systemic infection by methicillin-resistant Staphylococcus aureus K283 (MRSA) in neutropenic mice. Against urinary tract infection induced by Escherichia coli 851E in mice, LB20304a was more active than sparfloxacin and ciprofloxacin. However, LB 20304a was slightly less active than that of ciprofloxacin against urinary tract infection by Pseudomonas aeruginosa 1912E, but better than that of sparfloxacin.

• Biomolecules & Therapeutics
• /
• 제6권2호
• /
• pp.145-150
• /
• 1998

Administration of 3 type KGCs [recombinant human granulocyte colony-stimulating factor (rhG-CSF)] to mice with cyclophosphamide (CPA)-induced neutropenia for 4 consecutive days from the day after the CPA dosing (100 mg/kg) resulted in a dose dependent increase in the peripheral blood neutrophil count 6 hours after the final KGC injection. Within the KGC dose range of 0.1 to 40$\mu$g Per mouse Per day, there was a sigmoidal relationship between the logarithm of the dose and the peripheral blood neutrophil count (relative value for neutrophil count of the basal dose) in the treated mice. The sigmoidal relationship of test KGC preparations shows that there is a saturation point in terms of efficacy. Compared with e(fact of KGC-Orange, Green, and Blue, KGC-Orange recovers neutrophils more effectively than the others do.